Investors
News Release
Cyclacel's CYC065 Featured in Presentations at the American Association for Cancer Research Annual Meeting 2015
Mar 20 2015
BERKELEY HEIGHTS, N.J., March 20, 2015 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced that two abstracts highlighting preclinical data for Cyclacel's novel cyclin dependent kinase (CDK) inhibitor, CYC065, have been selected for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2015, being held on April 18 - 22, 2015 in Philadelphia.
Details for the presentations are as follows:
| Abstract: | 1650 |
| Title: | CYC065, a novel CDK2/5/9 inhibitor: detailed mechanistic studies, determinants of sensitivity and synergistic combinations |
| Date/Time: | Monday, April 20, 2015, 8:00AM -12:00 PM |
| Location: | Section 28, Poster Board 13 |
| Session Title: | Cell Cycle, DNA, and Transcription Targets |
| Authors: | Chiara Saladino, Sheelagh Frame, Susan Davis, David Blake, Daniella Zheleva, Cyclacel Limited, Dundee, UK |
| Abstract: | 3103 |
| Title: | Cyclin E amplification predicts sensitivity of primary Uterine Serous Carcinoma (USC) cell lines to the cdk2 inhibitor CYC065 |
| Date/Time: | Tuesday, April 21, 2015, 8:00AM -12:00 PM |
| Location: | Section 9, Poster Board 16 |
| Session Title: | Targeting Cyclin-Dependent Kinases and Checkpoint Kinases for Cancer Therapy |
| Authors: | Emiliano Cocco, Stefania Bellone, Salvatore Lopez, Elena Bonazzoli, Federica Predolini, Jonathan D. Black, Alessandro D. Santin, Yale University, New Haven, CT |
The abstracts can be accessed through the AACR website, www.aacr.org.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sapacitabine, Cyclacel's most advanced product candidate, is the subject of SEAMLESS, a Phase 3 trial, which has completed enrollment and is being conducted under an SPA with the FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly, and other studies for myelodysplastic syndromes (MDS) and chronic lymphocytic leukemia (CLL). Cyclacel's pipeline includes an oral regimen of seliciclib in combination with sapacitabine in a Phase 1 study of patients with Homologous Recombination (HR) repair-deficient breast, ovarian and pancreatic cancers, including gBRCA positive tumors, and CYC065, a novel CDK 2/9 inhibitor, with potential utility in both hematological malignancies and solid tumors. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.
© Copyright 2015 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.
CONTACT: Contacts for Cyclacel Pharmaceuticals, Inc.
Company:
Paul McBarron,
(908) 517-7330,
pmcbarron@cyclacel.com
Investor Relations:
Russo Partners LLC,
Robert Flamm,
(212) 845-4226,
robert.flamm@russopartnersllc.com